s-1743 and Cystic-Fibrosis

s-1743 has been researched along with Cystic-Fibrosis* in 2 studies

Trials

1 trial(s) available for s-1743 and Cystic-Fibrosis

ArticleYear
Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis.
    BMC pulmonary medicine, 2014, Feb-15, Volume: 14

    Gastro esophageal reflux (GER) is common in cystic fibrosis (CF) and may contribute to lung disease. Approximately 50% of patients with cystic fibrosis are being treated with proton pump inhibitors (PPIs).. In a randomized controlled study in adults, we compared treatment with esomeprazole 40 mg twice daily versus placebo in patients with CF and frequent respiratory exacerbations over a thirty-six week treatment period to determine effect on time to first exacerbation and other health related outcomes.. 17 patients without symptoms of GER were randomized and 15 completed the study. 13 subjects underwent 24 hour ambulatory pH probe monitoring; 62% had pH probe evidence of GER. Forty one percent of subjects had a pulmonary exacerbation during the study. There was no significant difference in time to first pulmonary exacerbation (log rank test p = 0.3169). Five of nine subjects in the esomeprazole group compared with 2 of eight subjects in the placebo group experienced exacerbations (esomeprazole vs. placebo: odds ratio = 3.455, 95% CI = (0.337, 54.294), Fisher's exact test: p = 0.334). There was no change in Forced Expiratory Volume in one second, Gastroesophageal Symptom Assessment Score or CF Quality of Life score between the two treatment groups.. There was a trend to earlier exacerbation and more frequent exacerbations in subjects randomized to esomeprazole compared with placebo. The effect of proton pump inhibitors on pulmonary exacerbations in CF warrants further investigation.. Clinicaltrials.gov, NCT01983774.

    Topics: Adult; Cystic Fibrosis; Disease Progression; Double-Blind Method; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lung Diseases; Male; Proton Pump Inhibitors

2014

Other Studies

1 other study(ies) available for s-1743 and Cystic-Fibrosis

ArticleYear
Complicated Clostridium difficile colitis in children with cystic fibrosis: association with gastric acid suppression?
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2014, Volume: 13, Issue:1

    Patients with cystic fibrosis (CF) have several risk factors for Clostridium difficile colonization such as frequent hospitalization and exposure to a broad array of antibiotics utilized for the control, eradication, and prophylaxis of respiratory pathogens. However, despite this high rate of colonization, the occurrence of C. difficile infection (CDI) in CF is rare. We report three children with CF who presented with severe community-associated CDI. All three children had complicated courses and one died. These children were in good health without significant morbidities, and were not frequently hospitalized nor did they receive frequent antibiotic courses. The occurrence of 3 severe cases within a 15-month period prompted us to report these cases and review the literature in regard to CDI. We reviewed the CF GI tract as possible risk factors for a high rate of C. difficile colonization in individuals with CF. Since a high percentage of individuals with CF are on gastric acid blocking agents, we also focused on gastric acid suppression as a potential risk factor for CDI.

    Topics: Adolescent; Antacids; Biopsy; Child; Clostridioides difficile; Colon; Cystic Fibrosis; Enterocolitis, Pseudomembranous; Esomeprazole; Fatal Outcome; Female; Gastric Acid; Humans; Infant; Male; Megacolon, Toxic; Proton Pump Inhibitors; Risk Factors

2014
chemdatabank.com